Neurotransmitter precursors treatment for new-drug abusers on their psychiatric symptoms

The effect of neurotransmitter precursors treatment on new-drug abusers’ psychiatric symptoms

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002492

Enrollment

Unknown

Registered

2012-06-06

Start date

2012-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

new-drug abuse

Interventions

1:tryptophan tablets

2:tyrosine tablets

3:tyrosine and tryptophan tablets

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. current new-drug abusers verified by the Structures Clinical Interview for the DSM-IV-TR; 2. 18 years of age or older; 3. willing and able to comply with the study; 4. willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. met dependence criteria for any substance other than new-drugs; 2. a history of dysfunction of liver, heart or kideny; 3. a current neurological or psychiatric disorder not due to new drugs; 4. serious endocrine and circulatory disorders; 5. not able to comply with the sduty procedure; 6. currently taking other psychiatric medications; 7. other circumstances.

Design outcomes

Primary

Measure	Time frame
SCL-90;AIS;	—

Countries

China

Contacts

Public ContactZengzhen Wang

wzzh@mails.tjmu.edu.cn+86 027 83657775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026